Autoantibodies to osteoprotegerin are associated with increased bone resorption in rheumatoid arthritis
Authors:
Open Access
- 1 August 2015
- journal article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 74 (8) , 1631-1632
Abstract
Osteoporosis is a common complication of many autoimmune diseases that is\ud typically attributed to disease specific factors rather than a direct autoimmune\ud process. This thesis arises from the investigation of a patient with severe high bone\ud turnover osteoporosis who was identified as having autoimmune disease but whose\ud osteoporosis deteriorated despite appropriate treatment. This presentation led to the\ud hypothesis that neutralising autoantibodies to the bone protective cytokine\ud osteoprotegerin (OPG) may have developed.\ud Serum from the index patient, but not healthy controls, was able to\ud immunoprecipitate recombinant OPG protein, demonstrating that OPG had become\ud the target of an autoimmune response. Purified immunoglobulins from the index case\ud were able to inhibit the function of OPG in vitro, by suppressing OPG-mediated\ud inhibition of a luciferase reporter cell line. This represents the first description of\ud disease associated with neutralising antibodies to OPG. Whilst the\ud immunoprecipitation assay did identify OPG antibodies in further patients these\ud results were difficult to quantify. A more robust enzyme linked immunosorbent\ud assay for OPG antibodies was developed using OPG as a capture antigen, which\ud allowed the screening of patient cohorts. Presence of OPG antibodies was defined as\ud a titre greater than the mean plus three standard deviations of 101 healthy volunteers.\ud A low prevalence of 14/864 (1.6%) was seen in a general population cohort and no\ud association with bone density or turnover was seen. An association with higher\ud vascular calcification score in this cohort requires replication. A prevalence of\ud 37/315 (11.7%) was seen in an osteoporosis cohort though no association was seen\ud with bone density or response to treatment. In a coeliac cohort OPG antibodies were\ud identified in 14/282 (5.0%) patients and presence of antibody was independently\ud associated with reduced spine bone density. Functional inhibition of OPG was shown\ud in vitro in 3/14 (21.4%) of the positive cases. Case finding of osteoporosis in the\ud coeliac cohort was not improved by identification of OPG antibodies. These results\ud are consistent with OPG antibodies being pathological in a small number of patients\ud with osteoporosis but a clinical utility of measuring OPG antibodies has not been\ud establishedKeywords
This publication has 8 references indexed in Scilit:
- Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodiesAnnals of the Rheumatic Diseases, 2014
- Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatmentNature Reviews Rheumatology, 2012
- Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentinJournal of Clinical Investigation, 2012
- Osteoporosis Associated with Neutralizing Autoantibodies against OsteoprotegerinNew England Journal of Medicine, 2009
- Focal and generalized bone loss in rheumatoid arthritis: separate or similar concepts?Nature Clinical Practice Rheumatology, 2008
- The Pathogenesis, Epidemiology and Management of Glucocorticoid-Induced OsteoporosisCalcified Tissue International, 2006
- OsteoporosisThe Lancet, 2006
- Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligandNature, 1999